FRED HUTCHINSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Employees: -

Market Cap: -

Website: https://www.fredhutch.org

Clinical Trials

Blood Samples to Identify Biomarkers in Haploidentical Graft Recipients

Completed

Conditions: Hodgkin Disease
Non-Hodgkin Lymphoma
Myelodysplastic Syndrome
Leukemia
Multiple Myeloma

First Posted Date: 2010-06-11

Last Posted Date: 2023-05-31

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 11

Registration Number: NCT01141959

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS

Phase 1

Completed

Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Untreated Adult Acute Myeloid Leukemia
de Novo Myelodysplastic Syndromes
Myelodysplastic Syndrome With Isolated Del(5q)

Interventions: Drug: bendamustine hydrochloride
Drug: idarubicin

First Posted Date: 2010-06-10

Last Posted Date: 2017-08-18

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 39

Registration Number: NCT01141725

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

A Trial Using Novel Markers to Predict Malignancy in Elevated-Risk Women

Not Applicable

Completed

Conditions: Epithelial Ovarian Cancer

Interventions: Procedure: CA125 assay on Abbott Architect i1000SR platform
Procedure: HE4 assay on Architect i1000SR platform
Procedure: Transvaginal Ultrasound

First Posted Date: 2010-05-12

Last Posted Date: 2018-12-13

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 854

Registration Number: NCT01121640

Locations: 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
🇺🇸
City of Hope, Duarte, California, United States

and more 2 locations

Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Metastatic Melanoma

Phase 1

Terminated

Conditions: Stage IV Melanoma

Interventions: Biological: therapeutic autologous lymphocytes
Biological: aldesleukin
Drug: cyclophosphamide
Procedure: biopsy

First Posted Date: 2010-04-19

Last Posted Date: 2011-12-21

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 12

Registration Number: NCT01106235

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Rituximab, Combination Chemotherapy, Filgrastim (G-CSF), and Plerixafor in Treating Patients With Non-Hodgkin Lymphoma Undergoing Mobilization of Autologous Peripheral Blood Stem Cells

Phase 2

Completed

Conditions: Non-Hodgkin Lymphoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Biological: Filgrastim
Drug: Ifosfamide
Procedure: Leukapheresis
Drug: Plerixafor
Biological: Rituximab

First Posted Date: 2010-04-01

Last Posted Date: 2018-01-23

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 20

Registration Number: NCT01097057

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Azacitidine in Treating Patients With Relapsed Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Childhood Myelodysplastic Syndromes
Adult Acute Myeloid Leukemia With Del(5q)
Recurrent Childhood Acute Myeloid Leukemia
Chronic Myelomonocytic Leukemia
Previously Treated Myelodysplastic Syndromes
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)

Interventions: Drug: azacitidine
Other: laboratory biomarker analysis

First Posted Date: 2010-03-10

Last Posted Date: 2017-05-24

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 43

Registration Number: NCT01083706

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Not Applicable

Terminated

Conditions: Adult Acute Lymphoblastic Leukemia in Remission
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Chronic Phase Chronic Myelogenous Leukemia
de Novo Myelodysplastic Syndromes
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Noncontiguous Stage II Grade 2 Follicular Lymphoma
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Noncontiguous Stage II Adult Burkitt Lymphoma
Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma

Interventions: Drug: plerixafor
Biological: filgrastim
Procedure: peripheral blood stem cell transplantation
Procedure: allogeneic hematopoietic stem cell transplantation

First Posted Date: 2010-02-26

Last Posted Date: 2017-06-28

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 1

Registration Number: NCT01076270

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Spouses/Partners Expressing Their Thoughts After Transplant

Not Applicable

Completed

Conditions: Cancer
Hematopoietic Stem Cell Transplantation

Interventions: Behavioral: Emotional expression

First Posted Date: 2010-02-03

Last Posted Date: 2010-02-08

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 122

Registration Number: NCT01061801

Locations: 🇺🇸
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States

Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies

Phase 2

Completed

Conditions: Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Blastic Phase Chronic Myelogenous Leukemia
de Novo Myelodysplastic Syndromes
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Childhood Acute Myeloid Leukemia in Remission
Childhood Myelodysplastic Syndromes
Recurrent Adult Acute Myeloid Leukemia

Interventions: Drug: fludarabine phosphate
Drug: busulfan
Biological: anti-thymocyte globulin
Drug: tacrolimus
Drug: methotrexate
Procedure: peripheral blood stem cell transplantation
Procedure: allogeneic hematopoietic stem cell transplantation
Other: laboratory biomarker analysis